The effects of ε-aminocaproic acid on fibrinolysis and thrombin generation during cardiac surgery

Anesthesia and Analgesia

Volumn 85, Issue 6, 1997, Pages 1221-1226

  Slaughter, Thomas F ^a   Faghih, Fariba ^a   Greenberg, Charles S ^a   Leslie, John B ^b   Sladen, Robert N ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; APROTININ; HEMOCHRON; HETASTARCH; THROMBIN; UNCLASSIFIED DRUG; ANTIFIBRINOLYTIC AGENT; ANTITHROMBIN III; ANTITHROMBIN III PROTEASE COMPLEX; ANTITHROMBIN III-PROTEASE COMPLEX; FIBRIN; PEPTIDE HYDROLASE;

ADULT; ANESTHESIA INDUCTION; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME INHIBITION; FEMALE; FIBRINOLYSIS; HEART SURGERY; HEMODILUTION; HUMAN; HUMAN CELL; HYPERCOAGULABILITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE FUNCTION; THROMBOSIS; BIOSYNTHESIS; BLEEDING; CARDIOPULMONARY BYPASS; CONTROLLED CLINICAL TRIAL; MIDDLE AGED; POSTOPERATIVE COMPLICATION; PROSPECTIVE STUDY;

6-AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENTS; ANTITHROMBIN III; CARDIOPULMONARY BYPASS; CORONARY ARTERY BYPASS; DOUBLE-BLIND METHOD; FEMALE; FIBRIN; FIBRINOLYSIS; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PEPTIDE HYDROLASES; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; THROMBIN;

EID: 0031284642     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-199712000-00008     Document Type: Article

References (25)

1. Woodman RC, Harker LA. Bleeding complications associated with cardiopulmonary bypass. Blood 1990;76:1680-97.
2. Tanaka K, Takao M, Yada I, et al. Alterations in coagulation and fibrinolysis associated with cardiopulmonary bypass during open heart surgery. J Cardiothorac Anesth 1989;3:181-8.
3. Stibbe J, Kluft C, Brommer EJP, et al. Enhanced fibrinolytic activity during cardiopulmonary bypass in open-heart surgery in man is caused by extrinsic (tissue-type) plasminogen activator. Eur J Clin Invest 1984;14:375-82.
4. Hardy JF, Belisle S. Natural and synthetic antifibrinolytics in adult cardiac surgery: efficacy, effectiveness, and efficiency. Can J Anaesth 1994;41:1104-12.
5. Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs 1985;29:236-61.
6. Van Oeveren W, Harder MP, Roozendaal KJ, et al. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990;99:788-97.
7. Cosgrove DM III, Heric B, Lytle BW, et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg 1992;54:1031-6.
8. Dentz ME, Slaughter TF, Mark JB. Early thrombus formation on heparin-bonded pulmonary artery catheters in patients receiving epsilon aminocaproic acid. Anesthesiology 1995;82:583-6.
9. Bohrer H, Fleishcher F, Lang J, Vahl C. Early formation of thrombi on pulmonary artery catheters in cardiac surgical patients receiving high-dose aprotinin. J Cardiothorac Anesth 1990;4:222-5.
10. Slaughter TF, LeBleu TH, Douglas JM, et al. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers. Anesthesiology 1994;80:520-6.
11. Bidstrup BP, Underwood SR, Sapsford RN, Streets EM. Effect of aprotinin (Trasylol) on aorta-coronary bypass graft patency. J Thorac Cardiovasc Surg 1993;105:147-52.
12. Havel M, Grabenwoger F, Schneider J, et al. Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood. J Thorac Cardiovasc Surg 1994;107:807-10.
13. Lemmer JH Jr, Stanford W, Bonney SL, et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency - a multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg 1994;107:543-53.
14. Levin EG, Marzec U, Anderson J, Harker LA. Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells. J Clin Invest 1984;74:1988-95.
15. Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N Engl J Med 1992;326:800-6.
16. Fareed J, Bick RL, Hoppensteadt DA, et al. Molecular markers of hemostatic activation. Clin Lab Med 1995;15:39-61.
17. Nossel HL. Relative proteolysis of the fibrinogen B beta chain by thrombin and plasmin as a determinant of thrombosis. Nature 1981;291:165-7.
18. Lip GYH, Lowe GDO. Fibrin D-dimer: a useful clinical marker of thrombogenesis. Clin Sci 1995;89:205-14.
19. Nieuwenhuizen W. Soluble fibrin as a molecular marker for a pre-thrombotic state: a mini-review. Blood Coagul Fibrinolys 1993;4:93-6.
20. Bauer KA, Rosenberg RD. The pathophysiology of the pre-thrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood 1987; 70:343-50.
21. Tripodi A, Mannucci PM. Markers of activated coagulation and their usefulness in the clinical laboratory. Clin Chem 1996;42: 664-9.
22. Dietrich W, Dilthey G, Spannagl M, et al. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin pretreated patients undergoing open-heart surgery. Anesthesiology 1995;83: 679-89.
23. Daily PO, Lamphere JA, Dembitsky WP, et al. Effect of prophylactic epsilon-aminocaproic acid on blood loss and trans fusion requirements in patients undergoing first-time coronary artery bypass grafting. J Thorac Cardiovasc Surg 1994; 108:99-106.
24. Vander Salm TJ, Ansell JE, Okike ON, et al. The role of epsilonaminocaproic acid in reducing bleeding after cardiac operation: a double-blind randomized study. J Thorac Cardiovasc Surg 1988;95:538-40.
25. Horrow JC, Hlavacek J, Strong MD, et al. Prophylactic tranexamic acid decreases bleeding after cardiac operations. J Thorac Cardiovasc Surg 1990;99:70-4.